Summary.-Xenografts of 3 human malignant cell lines in congenitally athymic nude mice have been examined for susceptibility to BCG. Growth of all 3 tumours, a bladder carcinoma, a melanoma and a colon carcinoma, was suppressed when cells were injected in admixture with BCG. Distant injection of BCG was ineffective. Mice with progressive growths had no detectable anti-human antibody, and rejection of cells and BCG failed to confer protection against subsequent tumour challenge. These studies indicate that human malignant cells are susceptible to local BCGactivated host responses, and that athymic mouse xenografts may be a useful model for assessing the response of human tumours to such agents.
FOLLOWING THE WORK of Morton et al. (1970) , it is well established that intralesional injection of Bacillus CalmetteGue'rin (BCG) into cutaneous melanoma lesions in man may cause their regression (Goodnight & Morton, 1978) . Other tumours, including those of breast (Smith et al., 1973) , bladder (Morales et al., 1978) and prostate (Merrin et al., 1975) have been shown to regress after local infiltration with BCG, and recently intrapleural BCCQ has been reported to prolong postoperative survival of Stage I lung cancer patients (McKneally et al., 1976 (McKneally et al., , 1978 .
While comparable studies with a wide range of experimental animal tumours have also shown their susceptibility to locally applied bacterial adjuvants, principally BCG and C. parvum (reviewed by Milas & Scott, 1978; Baldwin & Pimm, 1978) , experimental techniques for studying the susceptibility of human tumours to this form of adjuvant contact suppression are clearly limited. However, in view of the current use of human tumour xenografts in mice for assessing their response to chemotherapeutic agents (Sonis et al., 1977; UICC Technical Report, 1974; Povlsen & Jacobsen 1975; Houghton & Houghton, 1978) , the present tests were carried out to examine their 47 susceptibility to BCG. These studies were modelled on those previously carried out with rat tumour xenografts in congenitally athymic nude mice (Pimm & Baldwin, 1975 harvested from in vitro culture (Table  III) . None of the sera reacted against T24 cells (Fl 0-00-001), although serum from heterozygous (nu/+) mice rejecting T24 cells reacted strongly (FT 0 79-1.00).
DISCUSSION
These studies demonstrate that cells of human tumours will produce progressive growth in congenitally athymic mice, and that this growth is prevented by BCG incorporated into the inoculum, not injected separately. Sere raised in heterozygous mice against normal human cells reacted with cells from xenografts, confirming the human characteristic of the cells.
In previous work, growth of rat tumour xenografts was similarly controlled by admixture with BCG or C. parvum (Pimm & Baldwin, 1975 , although the suippression in athymic mice was in accordance with that seen in syngeneic recipients, so that carcinogen-induced sarcomas and hepatomas were readily controlled, while only slight suppression (Chassoux & Salomon, 1975; Hopper et al., 1976; Moore & Nisbet, 1978; Keller, 1977) . The indication from the present work is that locally activated host responses can similarly control growth of human malignant cells in an in vivo environment. This too is unlikely to involve systemic immunological responses, since distantly injected BCG was ineffective, and mice rejecting human malignant cells and BCG were not immune to a challenge with cells alone. Also immunofluorescence tests with sera from mice bearing xenografts failed to detect anti-human antibody. These observations parallel previous studies with rat tumour xenografts, where athymic mice rejecting cells and BCG were not immune to further challenge, and had no detectable anti-rat antibody (Pimm & Baldwin, 1975 Pimm, 1977) . This work was supported by a grant from the Cancer Research Campaign, and was carried out with the skilled technical assistance of Mrs A. P. Hopper, Mrs B. A. Jones and Mrs S. J. Wealthall. BCG was supplied by Glaxo Laboratories, Greenford, Middlesex, and the tissue culture lines were made available by Dr M. J. Embleton.
